You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
B
Not yet recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • loncastuximab tesirine
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
2022-01-24
Jan 24, 2022
U
Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • (no location specified)
2022-02-02
Feb 2, 2022
D
Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-09-08
Sep 8, 2021
C
Not yet recruiting
  • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
  • With and Without MyD88 and/or CD79B Mutations
  • (no location specified)
2022-04-01
Apr 1, 2022
R
Not yet recruiting
  • Diffuse Large B Cell Lymphoma
    • (no location specified)
    2021-12-27
    Dec 27, 2021
    N
    Recruiting
    • Non-Hodgkin's Lymphoma
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2022-04-07
    Apr 7, 2022
    C
    Active, not recruiting
    • Grade 3b Follicular Lymphoma
    • +15 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Duarte, California
      City of Hope Medical Center
    2022-02-17
    Feb 17, 2022
    U
    Active, not recruiting
    • Diffuse Large B-cell Lymphoma
    • HIV
    • Lilongwe, Malawi
      UNC Project, Lighthouse Trust
    2021-10-18
    Oct 18, 2021
    S
    Recruiting
    • Diffuse Large B-cell Lymphoma
    • Shanghai, Shanghai, China
      Ruijin Hospital, Shanghai JiaoTong University School of Medicine
    2021-12-30
    Dec 30, 2021
    O
    Recruiting
    • Diffuse Large B-Cell Lymphoma
    • +3 more
    • Molecular Nanotechnology
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    2021-03-15
    Mar 15, 2021
    R
    Active, not recruiting
    • CD20 Positive
    • +6 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    2021-10-11
    Oct 11, 2021
    C
    Recruiting
    • Diffuse Large B-cell Lymphoma
    • TQ-B3525 tablets
    • Beijing, Beijing, China
    • +1 more
    2021-08-17
    Aug 17, 2021
    S
    Completed
    • Lymphoma, Large B-Cell, Diffuse
    • Gene Expression Profiling
    • Gene expression profile
    • Shanghai, Shanghai, China
      Yian Zhang
    2022-03-31
    Mar 31, 2022
    C
    Recruiting
    • Diffuse Large B Cell Lymphoma
    • 18F-FDG PET SCAN
    • MRI DIFFUSION
    • Nice, France
      Centre antoine-LACASSAGNE
    2021-11-09
    Nov 9, 2021
    D
    Recruiting
    • Diffuse Large B-Cell Lymphoma
    • Cleveland, Ohio
      Cleveland Clinic Taussig Cancer institute, Case Comprehensive Ca
    2022-02-02
    Feb 2, 2022
    T
    Active, not recruiting
    • Lymphoma, B-Cell
    • San Antonio, Texas
      Mays Cancer Center, UT Health San Antonio
    2022-03-09
    Mar 9, 2022
    A
    Not yet recruiting
    • Diffuse Large B-cell Lymphoma
    • (no location specified)
    2022-02-22
    Feb 22, 2022
    S
    Completed
    • Lymphoma, Large B-Cell, Diffuse
    • FDG PET radiomic feature evaluation
    • Hangzhou, Zhejiang, China
      Second Affiliated Hospital, School of Medicine, Zhejiang Univers
    2021-09-27
    Sep 27, 2021
    H
    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Central Nervous System Metastasis
      • Herlev, Capital Region, Denmark
        Herlev Hopital
      2022-03-21
      Mar 21, 2022
      I
      Recruiting
      • Diffuse Large B-cell Lymphoma
      • Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.
      • Toulouse, France
        Institut Universitaire du Cancer Toulouse - Oncopole
      2022-03-28
      Mar 28, 2022
      A
      Active, not recruiting
      • Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
      • Los Angeles, California
      • +6 more
      2022-03-21
      Mar 21, 2022
      E
      Not yet recruiting
      • Relapsed/Refractory Multiple Myeloma
      • Relapsed/Refractory Diffuse Large B-Cell Lymphoma
      • Boston, Massachusetts
      • +2 more
      2021-12-16
      Dec 16, 2021
      B
      Not yet recruiting
      • Relapsed Diffuse Large B-cell Lymphoma
      • Refractory Diffuse Large B-cell Lymphoma
      • (no location specified)
      2022-02-23
      Feb 23, 2022
      A
      No longer available
      • Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
      • Loncastuximab Tesirine
      • (no location specified)
      2021-05-10
      May 10, 2021
      C
      Not yet recruiting
      • Diffuse Large B-cell Lymphoma
      • Anlotinib Hydrochloride Capsules
      • Beijing, Beijing, China
        Cancer Hospital Chinese Academy of Medical Sciences
      2021-03-30
      Mar 30, 2021